In the case of hepatitis B, drug treatment depends on the severity of the course. If the body is unable to fight the hepatitis B viruses sufficiently, hepatitis B cannot be completely cured even with medication. However, by supporting the immune system in fighting the virus or suppressing viral replication, the risk of developing severe liver damage or secondary diseases can be reduced. The risk of infection can also be reduced by drug treatment.
For hepatitis C, drugs with completely novel modes of action have been developed in recent years. They intervene directly at different points in the multiplication cycle of the hepatitis C virus and are therefore referred to as direct antiviral agents (DAAs).